Pegylated IFN-β-1a provided a statistically significant reduction in the annualized relapse rate (ARR) by 35·6% (P < 0·001, 2-week dosing) and 27·5%
(P < 0·02m 4-week dosing) compared to placebo. Moreover, pegylated IFN-β-1a reduced the risk of 12-week confirmed disability progression by 38% in both dosing arms (P < 0·04) and was superior to placebo across a range of MRI parameters. Both dosing regimens showed favourable safety and tolerability profiles. The overall incidence of severe adverse events and adverse events was similar between the IFN-β-1a and placebo groups. The most common severe adverse events were infections (≤1% per group). The most commonly reported adverse events associated with pegylated IFN-β-1a treatment were redness at the injection site and influenza-like illness. Based on these data, Biogen is aiming for fast-track AZD3965 cost approval of pegylated IFN-β-1a for patients with RRMS in the United States and Europe in 2013. In contrast, treatment with IFN-β-1a has failed to provide beneficial effects in patients with CIDP [23-25]. Adverse effects, frequent: flu-like symptoms, inflammation, redness and indurations at the side of puncture, induction or aggravation of depression and suicidality, aggravation of spasticity,
elevation of liver enzymes; infrequent: aseptic skin necrosis, toxic hepatitis, leukopenia. Preparation and administration: in CIS and RRMS, immunomodulation with GA [12, 19-21] serves as basic therapy, which should CH5424802 solubility dmso be initiated as soon as possible after the diagnosis has PtdIns(3,4)P2 been properly established. GA (Copaxone®) is injected subcutaneously at a dose of 20 mg daily. Clinical trials: a Phase III clinical trial (a study in subjects with RRMS to assess the efficacy, safety and tolerability of GA injection
40 mg administered three times a week compared to placebo – GALA) compared efficacy, safety and tolerability of GA injected s.c. at a dose of 40 mg thrice weekly to placebo in 1404 RRMS patients. The annualized relapse rate was reduced by 34·4% in the GA group versus placebo (P < 0·0001). At 12 months, the cumulative number of new/enlarging T2 lesions (34·7% reduction, P < 0·0001) and gadolinium enhanced (GdE) lesions (44·8% reduction, P < 0·0001) were significantly lower in GA-treated patients. Hence, GA at 40 mg thrice weekly may provide a potential alternative therapeutic option of using a higher dose of GA at a reduced injection frequency, but direct comparison to the standard dosing regimen of 20 mg daily has not been performed [26]. GA has not (yet) been tested in patients with CIDP. Adverse effects, frequent: local side effects at the site of puncture (itching, redness, swelling, inflammation), lymph node swelling; infrequent: systemic post-injection reaction (SPIR), anaphylactic reactions. IVIG consist of pooled polyclonal immunoglobulins derived from healthy donors.